ArticleBritish journal of cancer2015
Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM.
Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 45 citations in OpenAlex.
- Integrated Proteogenomic Approach for Discovering Potential Biomarkers in Urothelial Carcinoma of the Bladder.Biomedicines · 2025Article
- Phytochemicals as Chemo-Preventive and Therapeutic Agents Against Bladder Cancer: A Comprehensive Review.Diseases (Basel, Switzerland) · 2025Review
- High P2X6 receptor expression in human bladder cancer predicts good survival prognosis.Molecular and cellular biochemistry · 2022Article
- Quinazoline Derivatives as Potential Therapeutic Agents in Urinary Bladder Cancer Therapy.Frontiers in chemistry · 2021Review
- Prognostic Value of an Immunohistochemical Signature in Patients With Bladder Cancer Undergoing Radical Cystectomy.Frontiers in oncology · 2021Article
- Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer.Frontiers in molecular biosciences · 2021Review
- Role of tyrosine kinases in bladder cancer progression: an overview.Cell communication and signaling : CCS · 2020Review
- Shedding light on the EpCAM: An overview.Journal of cellular physiology · 2019Review
- Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.International journal of biological sciences · 2019Article
- Antibody-Drug Conjugates in Bladder Cancer.Bladder cancer (Amsterdam, Netherlands) · 2018Review
- Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification.Oncotarget · 2018Article
- SheddomeDB: the ectodomain shedding database for membrane-bound shed markers.BMC bioinformatics · 2017Review
- A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer.Bladder cancer (Amsterdam, Netherlands) · 2016Article
- Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk.Scientific reports · 2016Article
- Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of -omics findings.Scientific reports · 2016Article
- Use ofProteomes · 2015Article
- Bladder cancer: Urinary EGFR and EpCAM predict cancer-specific survival.Nature reviews. Urology · 2015Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundBetter biomarkers must be found to develop clinically useful urine tests for bladder cancer. Proteomics can be used to identify the proteins released by cancer cell lines and generate candidate markers for developing such tests.
methodsWe used shotgun proteomics to identify proteins released into culture media by eight bladder cancer cell lines. These data were compared with protein expression data from the Human Protein Atlas. Epidermal growth factor receptor (EGFR) was identified as a candidate biomarker and measured by ELISA in urine from 60 noncancer control subjects and from 436 patients with bladder cancer and long-term clinical follow-up.
resultsBladder cancer cell lines shed soluble EGFR ectodomain. Soluble EGFR is also detectable in urine and is highly elevated in some patients with high-grade bladder cancer. Urinary EGFR is an independent indicator of poor bladder cancer-specific survival with a hazard ratio of 2.89 (95% CI 1.81-4.62, P<0.001). In multivariable models including both urinary EGFR and EpCAM, both biomarkers are predictive of bladder cancer-specific survival and have prognostic value over and above that provided by standard clinical observations.
conclusionsMeasuring urinary EGFR and EpCAM may represent a simple and useful approach for fast-tracking the investigation and treatment of patients with the most aggressive bladder cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.